November 9, 2016 11:01 AM ESTUpdated 02:18 PM

Kite gives itself a little more time to finish FDA application for KTE-C19

Arsalan Arif

Founder

Kite Pharma has given itself until Q1 2017 to complete the BLA filing for KTE-C19, its pioneering engineered T-cell therapy. That’s a slight pushback of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kite gives itself a little more time to finish FDA application for KTE-C19

Arsalan Arif

Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Kite gives it­self a lit­tle more time to fin­ish FDA ap­pli­ca­tion for KTE-C19

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Kite gives itself a little more time to finish FDA application for KTE-C19

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers